Inovio Pharmaceuticals Inc. Stock Falls 21.9%, Underperforms Peers
Dow Jones2026/10/30 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Inovio Pharmaceuticals Inc. plummeted 21.9% to $0.60 on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 2.9% to 25,437.00 and Dow Jones Industrial Average falling 1.1% to 51,770.31.
This was the stock's second consecutive day of losses.
Inovio Pharmaceuticals Inc. closed 77.9% short of its 52-week high of $2.72, which the company reached on December 17th.
The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 0.7% to $273.20, Statera Biopharma Inc. remained unchanged, and Pfizer Inc. rose 1.90% to $30.52.
Trading volume totaled 17.1 million, compared to the 50-day average of 3.7 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 30, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3 Catalysts Cramer Says Could Extend the Nasdaq Sell-Off This Week
Meta (META.US) AI shopping assistant Muse tests e-commerce, Amazon (AMZN.US) faces potential impact on nearly $70 billion advertising business
Meta Platforms (META.US) has launched its new AI shopping assistant, Muse, which is emerging as a potential threat to Amazon. Muse may challenge the e-commerce giant’s dominance in online shopping and its nearly 70 billion USD advertising business.
Crypto prices
More
